SG Americas Securities LLC Boosts Stake in DaVita Inc. $DVA

SG Americas Securities LLC grew its holdings in DaVita Inc. (NYSE:DVA) by 27.4% during the 1st quarter, HoldingsChannel.com reports. The firm owned 212,293 shares of the company’s stock after buying an additional 45,609 shares during the period. SG Americas Securities LLC’s holdings in DaVita were worth $32,627,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. Elevation Wealth Partners LLC increased its position in shares of DaVita by 147.3% during the 4th quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock worth $31,000 after purchasing an additional 165 shares during the last quarter. Caitlin John LLC acquired a new position in DaVita in the fourth quarter valued at about $34,000. Sankala Group LLC purchased a new position in DaVita during the fourth quarter worth about $39,000. Canada Pension Plan Investment Board purchased a new position in DaVita during the second quarter worth about $43,000. Finally, Kestra Advisory Services LLC acquired a new stake in shares of DaVita during the fourth quarter valued at about $45,000. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Stock Performance

NYSE DVA opened at $211.11 on Wednesday. The firm has a market cap of $13.55 billion, a price-to-earnings ratio of 19.58, a PEG ratio of 0.69 and a beta of 0.91. The firm has a 50 day simple moving average of $184.62 and a 200-day simple moving average of $150.69. DaVita Inc. has a one year low of $101.00 and a one year high of $215.33.

DaVita (NYSE:DVA) last announced its earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, topping the consensus estimate of $2.33 by $0.54. The firm had revenue of $3.42 billion for the quarter, compared to the consensus estimate of $3.36 billion. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The firm’s revenue for the quarter was up 6.0% on a year-over-year basis. During the same period in the prior year, the firm earned $2.00 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities analysts predict that DaVita Inc. will post 15.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Barclays upped their price objective on shares of DaVita from $158.00 to $194.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th. Deutsche Bank Aktiengesellschaft raised DaVita from a “hold” rating to a “buy” rating and boosted their target price for the company from $126.00 to $220.00 in a research report on Wednesday, May 6th. Truist Financial upped their price target on DaVita from $158.00 to $205.00 and gave the stock a “hold” rating in a research note on Friday, May 8th. UBS Group raised their price target on DaVita from $190.00 to $235.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of DaVita in a report on Monday, June 8th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $199.17.

Insiders Place Their Bets

In related news, CFO Joel Ackerman sold 51,471 shares of the business’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the completion of the transaction, the chief financial officer directly owned 132,434 shares of the company’s stock, valued at $25,440,571.40. The trade was a 27.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Kathleen Alyce Waters sold 15,405 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the sale, the insider directly owned 109,194 shares in the company, valued at $22,756,029.60. This represents a 12.36% decrease in their position. The disclosure for this sale is available in the SEC filing. 1.50% of the stock is currently owned by corporate insiders.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.